Beijing Tide Pharmaceutical Co. Ltd. has identified protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer and myelofibrosis.
Prelude Therapeutics Inc. has described proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase binding moiety covalently linked to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) or transcription activator BRG1 (SMARCA4; BAF190A; SNF2-β) targeting moiety through a linker. They are reported to be useful for the treatment of cancer.
Altay Therapeutics Inc. has divulged signal transducer and activator of transcription 3 (STAT3) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, diabetes, inflammatory disorders, muscular dystrophy, neurodegeneration and thyroid disorders.
Sensorium Therapeutics Inc. has identified mesembrine analogues acting as serotonin transporter (SERT) inhibitors reported to be useful for the treatment of neurological disorders.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized cytochrome P450 11B2, mitochondrial (CYP11B2; aldosterone synthase; ALDOS) inhibitors reported to be useful for the treatment of hypertension, diabetic nephropathy, chronic kidney disease and primary aldosteronism.
Transition Bio Ltd. has disclosed YTH domain-containing protein 1 (YTHDC1; YT521-B) inhibitors reported to be useful for the treatment of acute myeloid leukemia (AML).
Nanjing Synnocare Pharmaceutical Technology Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Galapagos NV has divulged probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α) inhibitors reported to be useful for the treatment of cancer.
RSS